Calamos Advisors LLC Invests $289,000 in OptimizeRx Corp. (NASDAQ:OPRX)

Calamos Advisors LLC bought a new position in shares of OptimizeRx Corp. (NASDAQ:OPRX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 33,399 shares of the company's stock, valued at approximately $289,000. Calamos Advisors LLC owned 0.18% of OptimizeRx at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of OPRX. SBI Securities Co. Ltd. purchased a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $25,000. Royce & Associates LP purchased a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $5,198,000. Perkins Capital Management Inc. raised its stake in shares of OptimizeRx by 4.4% in the 4th quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company's stock valued at $514,000 after acquiring an additional 4,450 shares during the period. JPMorgan Chase & Co. raised its stake in shares of OptimizeRx by 670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company's stock valued at $291,000 after acquiring an additional 52,169 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of OptimizeRx by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock valued at $1,948,000 after acquiring an additional 4,821 shares during the period. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Stock Down 4.4%

NASDAQ OPRX traded down $0.58 on Friday, hitting $12.70. 172,372 shares of the stock were exchanged, compared to its average volume of 302,495. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.25. OptimizeRx Corp. has a fifty-two week low of $3.78 and a fifty-two week high of $15.71. The company has a market cap of $234.95 million, a PE ratio of -15.12, a PEG ratio of 4.43 and a beta of 1.34. The company has a 50-day moving average price of $12.58 and a 200-day moving average price of $8.70.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative net margin of 16.33% and a negative return on equity of 0.29%. The company had revenue of $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. Sell-side analysts anticipate that OptimizeRx Corp. will post -0.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OPRX has been the topic of a number of research analyst reports. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Citigroup reissued an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. JMP Securities lifted their price objective on shares of OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a report on Tuesday, May 13th. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Stifel Nicolaus lifted their price objective on shares of OptimizeRx from $12.50 to $16.00 and gave the company a "buy" rating in a report on Monday, June 9th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, OptimizeRx has an average rating of "Moderate Buy" and an average price target of $10.81.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.